Chongqing Runze Pharmaceutical Co., Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
1
Ending by 2030
Sep 2030
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 7, 2027The maintenance fee for Preparation method for medical porous tantalum implant material (US 9,072,811) comes due Jan 7, 2027. Unpaid by Jul 7, 2027, it lapses early.
- 2 fees due Mar 8, 2027
- 1 fee due Jul 19, 2027The maintenance fee for Crystal form I of (S)-4-hydroxy-2-oxo-1-pyrrolidine acetamide, preparing method and use thereof (US 9,238,622) comes due Jul 19, 2027. Unpaid by Jan 19, 2028, it lapses early.
- 1 fee due Sep 24, 2027The maintenance fee for Porous material (US 10,597,755) comes due Sep 24, 2027. Unpaid by Mar 24, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,238,622 | Crystal form I of (S)-4-hydroxy-2-oxo-1-pyrrolidine acetamide, preparing method and use thereof In force · USPTO record | In force | USPTO record | |
| US 9,126,928 | 4-hydroxy-2-oxo-1-pyrrolidineacetamide racemate crystal form I and preparation method therefor In force · USPTO record | In force | USPTO record | |
| US 9,126,929 | (S)-4-hydroxy-2-oxo-1-pyrrolidineacetamide racemate crystal form II and preparation method therefor In force · USPTO record | In force | USPTO record | |
| US 9,532,975 | Use of levo-oxiracetam and oxiracetam in preparation of medicines for preventing or treating coma In force · USPTO record | In force | USPTO record | |
| US 9,427,268 | Porous tantalum rod In force · USPTO record | In force | USPTO record | |
| US 9,072,811 | Preparation method for medical porous tantalum implant material In force · USPTO record | In force | USPTO record | |
| US 9,670,156 | Crystal form III of (S)-oxiracetam, preparation method and use thereof In force · USPTO record | In force | USPTO record | |
| US 10,597,755 | Porous material In force · USPTO record | In force | USPTO record | |
| US 10,835,641 | Porous material and preparation method thereof In force · USPTO record | In force | USPTO record | |
| US 10,822,283 | Porous material and preparation method thereof In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 11: 12 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
7 no status recorded